Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter Randomized Double-Blind Placebo-Controlled Phase 2 Trial of SRP-9001 in Duchenne Muscular Dystrophy
2021-000078-27Phase 2
- Sponsor
- Sarepta Therapeutics
- Start
- Nov 2022
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing SRP-9001 with Placebo (2 arms). Primary endpoint: Change From Baseline in Quantity of Micro-dystrophin Protein Expression as Measured by Western Blot.
02
Drugs
delandistrogene moxeparvovec
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2021-000078-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000078-27.